Literature DB >> 9596658

Growth inhibition of granulocyte-macrophage colony-forming cells by human cytidine deaminase requires the catalytic function of the protein.

C Gran1, A Bøyum, R F Johansen, D Løvhaug, E C Seeberg.   

Abstract

Previous studies have indicated that cytidine deaminase (CDD) is a potent growth inhibitor of granulocyte-macrophage colony-forming cells (GM-CFC). In this study, we have undertaken molecular cloning and purification of recombinant human CDD to elucidate the growth regulatory potential and mechanism behind the growth suppressive effect. The purified protein had a specific activity of 1.35 x 10(5) U/mg and a Km value of 30 micromol/L. In the GM-CFC assay, the recombinant protein was shown to reduce colony formation to 50% at 16 pmol/L concentration. Similarly, as was observed with CDD derived from granulocyte extract, the effect depended on the presence of thymidine (>/= 4 x 10(-5) mol/L). These results imply that CDD is an extremely potent inhibitor of GM-CFC and that no additional factor from the granulocyte extract is required for the growth inhibitory effect. Modification of CDD by truncation from the C-terminal end, or by amino acid substitution of an active site glutamate residue, eliminated both the enzyme activity and the growth regulatory potential of CDD. Furthermore, CDD from Escherichia coli was found to be even more effective than human CDD in growth suppression of GM-CFC, with 10-fold higher inhibitory activity corresponding to a 10-fold higher enzymatic activity. Taken together, these results show that the catalytic nucleoside deaminating function of the protein is essential for the growth suppressive effect of CDD. Most probably, CDD exerts growth inhibition by depleting the cytidine and deoxycytidine pool required for DNA synthesis, as addition of deoxycytidine monophosphate, which is not a substrate for CDD, neutralizes the inhibiting effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596658

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter.

Authors:  Sara M Fitzgerald; Rakesh K Goyal; William R A Osborne; Jennifer D Roy; John W Wilson; R E Ferrell
Journal:  Hum Genet       Date:  2006-01-31       Impact factor: 4.132

Review 2.  Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy.

Authors:  Nico Lachmann; Sebastian Brennig; Ruhi Phaltane; Michael Flasshove; Dagmar Dilloo; Thomas Moritz
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

3.  Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.

Authors:  Daniela Micozzi; Francesco Martino Carpi; Stefania Pucciarelli; Valeria Polzonetti; Paolo Polidori; Santiago Vilar; Brian Williams; Stefano Costanzi; Silvia Vincenzetti
Journal:  Int J Biol Macromol       Date:  2013-10-29       Impact factor: 6.953

4.  Calprotectin (S100A8/S100A9) and myeloperoxidase: co-regulators of formation of reactive oxygen species.

Authors:  Arne Bøyum; Knut Kristian Skrede; Oddvar Myhre; Vivi-Ann Tennfjord; Christine Gran Neurauter; Helge Tolleshaug; Eirunn Knudsen; Per Kristian Opstad; Magnar Bjørås; Haakon B Benestad
Journal:  Toxins (Basel)       Date:  2010-01-20       Impact factor: 4.546

5.  Time since onset of disease and individual clinical markers associate with transcriptional changes in uncomplicated dengue.

Authors:  Cornelia A M van de Weg; Henk-Jan van den Ham; Maarten A Bijl; Fatih Anfasa; Fatiha Zaaraoui-Boutahar; Beti E Dewi; Leonard Nainggolan; Wilfred F J van IJcken; Albert D M E Osterhaus; Byron E E Martina; Eric C M van Gorp; Arno C Andeweg
Journal:  PLoS Negl Trop Dis       Date:  2015-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.